You are subscribed to the Ophthalmology Times eNews.

View Online | Download Magazine | Share With A Colleague | Print & Digital Subscribe | eNewsletter Subscribe

Saturday — April 18, 2015

Welcome!

Ophthalmology Times welcomes ophthalmic professionals from around the world to San Diego. Our four-day coverage of this year’s meeting of the American Society of Cataract and Refractive Surgery begins today and includes the latest research findings and clinical news of interest to readers. Enjoy the meeting!

What the future holds in glaucoma therapies

The present method of lowering IOP as a means of preventing optic neuropathy is expanding beyond prostaglandin analogues and beta blockers to include novel therapeutics, such as ROCK inhibitors, the adenosine class of drugs, and nitric oxide added to prostaglandins, said John R. Samples, MD. » Read about the future of glaucoma therapy

Can Schlemm's canal surgery be glaucoma's Holy Grail?

Glaucoma surgeons are constantly clamoring for better surgical techniques. These new procedures will have to include less follow-up, fewer complications, and be technically accessible, said Barbara Smit, MD, PhD.
» Click for the answer

Changing nature of combat brings new ocular injury challenges

When military personnel are injured in combat situations, the primary concern of saving lives supersedes saving sight, said Col. Anthony J. Johnson, MD, Fort Sam Houston, Antonio, TX. » Click to find out why

Emerging pandemics require 'high degree of alertness'

A number of emerging infectious diseases have made recent headlines—most prominently, the Ebola virus outbreak in West Africa—prompting higher levels of vigilance, said Paul Tambyah, MD, PhD, Singapore. » Click to read how to prevent pandemics

FROM THE SHOW FLOOR

FDA approves AcuFocus corneal inlay

The approval of the Kamra corneal inlay represents a major advancement in the surgical correction of presbyopia in more than a decade, according to its manufacturer. » Click for more on the device

Alcon receives FDA approval of new multifocal IOL

Alcon Laboratories has received FDA approval for its AcrySof IQ ReSTOR +2.5 D IOL for patients undergoing cataract eye surgery who choose to address near, intermediate, and distance vision needs at the same time. » Click for more on the approval

Isaac Porter, MD @eyePorter

Rajesh Fogla, MD predicts the increased use of intraoperative OCT for DALK corneal transplants #WCCVII #ASCRSASOA2015

ASCRS @ASCRStweets

NEW Femtosecond Laser Cataract Surgery sessions in San Diego on 4/20! Learn more and register #ASCRSASOA2015 http://ow.ly/LJMvD

AAO @aao_ophth

In San Diego for at #ASCRSASOA2015? Increase understanding with new patient education materials -- see them at Booth #917

Top Tweets

We welcome your feedback!
Please send your comments to:

Mark L. Dlugoss

Group Content Director

UBM Advanstar Eyecare Group

[email protected]

DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times.
The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA.
For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular.

Editorial Questions? Contact the Editorial Team Click Here. Sales, Reprints, Classified questions? Contact the Sales Team Click Here.